Investor News

ARDSLEY, N.Y.--(BUSINESS WIRE)--
Acorda Therapeutics, Inc. (Nasdaq:ACOR)
today announced the pricing of a public offering of $300 million
principal amount of convertible senior notes due 2021 (the "Notes"). The
Notes will bear interest at an annual rate of 1.75% and will mature on
June 15, 2021, unless earlier converted, purchased or redeemed. Acorda
granted the underwriter an option to purchase up to an additional $45
million principal amount of Notes to cover over-allotments, if any.

The Notes will be convertible prior to December 15, 2020 only under
certain circumstances and during certain periods, and will be
convertible thereafter regardless of those circumstances. The conversion
rate will initially be 23.4968 shares of Acorda’s common stock per
$1,000 principal amount of Notes (equivalent to an initial conversion
price of approximately $42.56 per share of Acorda’s common stock),
subject to adjustment in certain circumstances. Upon conversion, the
Notes may be settled, at Acorda's election, in cash, shares of Acorda's
common stock or a combination of cash and shares of Acorda's common
stock.

Acorda intends to use the net proceeds from this offering for general
corporate purposes, including to fund possible acquisitions of, or
investments in, complementary businesses, products and technologies.
Acorda has not entered into any agreements or commitments with respect
to any acquisitions or investments at this time.

J.P. Morgan Securities LLC is acting as the sole book-running manager
for the Notes offering.

This press release will not constitute an offer to sell or a
solicitation of an offer to buy any securities nor will there be any
sale of these securities in any state in which such offer, solicitation
or sale would be unlawful prior to registration or qualification under
the securities laws of such state. The offering of the Notes is being
conducted pursuant to an effective shelf registration statement filed
with the Securities and Exchange Commission ("SEC") on June 16, 2014.
The offering of Notes will be made only by means of a prospectus and any
issuer free writing prospectus that Acorda may authorize in connection
therewith. Before you invest, you should read these documents and any
other document Acorda has filed with the SEC and incorporated therein
for more complete information about Acorda and the offering of the
Notes. You may retrieve these documents for free by visiting EDGAR on
the SEC Website at http://www.sec.gov.

Alternatively, copies of the offering documents can be obtained by
contacting J.P. Morgan Securities LLC, c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by
calling 1-866-803-9204.

Forward-Looking Statements

This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including with respect to the intended use of proceeds from the Notes
offering. All statements, other than statements of historical facts,
regarding management's expectations, beliefs, goals, plans or prospects
should be considered forward-looking. These statements are subject to
risks and uncertainties that could cause actual results to differ
materially, including Acorda’s ability to successfully market and sell
Ampyra in the U.S.; third party payers (including governmental agencies)
may not reimburse for the use of Ampyra or Acorda’s other products at
acceptable rates or at all and may impose restrictive prior
authorization requirements that limit or block prescriptions; the risk
of unfavorable results from future studies of Ampyra or from Acorda’s
other research and development programs, including Plumiaz (Acorda’s
trade name for Diazepam Nasal Spray), or any other acquired or
in-licensed programs; Acorda may not be able to complete development of,
obtain regulatory approval for, or successfully market Plumiaz or other
products under development; the occurrence of adverse safety events with
Acorda’s products; delays in obtaining or failure to obtain regulatory
approval of or to successfully market Fampyra outside of the U.S. and
Acorda’s dependence on its collaboration partner Biogen Idec in
connection therewith; competition, including the impact of generic
competition on Zanaflex Capsules revenues; Acorda’s failure to protect
its intellectual property, to defend against the intellectual property
claims of others or to obtain third party intellectual property licenses
needed for the commercialization of its products; failure to comply with
regulatory requirements could result in adverse action by regulatory
agencies; and the ability to obtain additional financing to support our
operations. These and other risks are described in greater detail in
Acorda’s filings with the SEC. Acorda may not actually achieve the goals
or plans described in its forward-looking statements, and investors
should not place undue reliance on these statements. Forward-looking
statements made in this release are made only as of the date hereof, and
Acorda disclaims any intent or obligation to update any forward-looking
statements as a result of developments occurring after the date of this
release.